ARMIZOL-IV

www.greencrossindia.com

Each tablet contains: Albendazole 400mg Ivermectin 12mg

ARMIZOL-IV Suspension

Each 5 ml contains:
Albendazole 200mg
Ivermectin 1.5mg

Albendazole; Belongs to the class of benzimidazole derivative agents used as antinematodal. Ivermectin; Belongs to the class of avermectine agents used as antinematodal.

MECHANISM OF ACTION

Ivermectin selectively binds and with high affinity to glutamate-gated and GABA (GABA)-gated chloride ion channels. This increases the permeability of the cell membrane to chloride ions leading to hyperpolarisation of muscles and nerve cells, thus ultimately causing paralysis and death of the parasites. Albendazole causes degenerative alterations in the intestinal cells of the worm by inhibiting polymerisation or assembly of tubules into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer and subsequent release of lysosomes result in decreased production of ATP (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilised and eventually dies.

INDICATIONS

ARMIZOL- IV is indicated for the treatment of the following infections:

Neurocysticercosis

A ARMIZOL- IV is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.Lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. Clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts.

Hydatid Disease

ARMIZOL- IV is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. This indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80-90% of patients given albendazole for 3 cycles of therapy of 28 days each. Clinical cure (disappearance of cysts) was seen in approximately 30% of these patients, and improvement (reduction in cyst diameter of ≥25%) was seen in an additional 40%.

ARMIZOL- IV can be indicated in the treatment of single or mixed intestinal parasites. Clinical studies have shown albendazole to be effective in the treatment of *Ascaris lumbricoides* (roundworm), *Trichuris trichiura* (whipworm), *Enterobius vermicularis* (pinworm/threadworm), *Ancylostoma duodenale* and *Necator americanus* (hookworm), *Taenia spp.* (tapeworm) and *Strongyloidesstercoralis*.

NOTE:

- When medically feasible, surgery is considered the treatment of choice for hydatid disease. When administering albendazole in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
- The efficacy of albendazole in the therapy of alveolar hydatid disease caused by Echinococcus multilocularis has not been clearly demonstrated in clinical studies.

DOSAGE AND ADMINISTRATION

Adult: Per tab contains ivermectin 12 mg and albendazole 400 mg: 1 tab once daily.. **Child:- Armizol –IV** Suspension: - Ivermectin 1.5 mg and Albendazole 200 mg: once daily.

CONTRAINDICATIONS

Hypersensitivity. Pregnancy, lactation. child <5 yrs or <15 kg body weight.

ADVERSE DRUG REACTION:

Diarrhoea, nausea, vomiting, dizziness, pruritus, urticaria, rash, arthralgia, fever, myalgia, asthenia, postural hypotension, tachycardia, oedema, lymphadenopathy, sore throat, cough, headache, somnolence, transient eosinophilia, raised liver enzyme values.

PACKAGING INFORMATION

ARMIZOL – IV TABblister pack of 1 tablet **ARMIZOL – IV SUSPENSION**10ml Pet Bottle

